Press release
Chengdu, China, July 30, 2026 — Anticancer Bioscience (ACB) announced that its Investigational New Drug (IND) application for JMBI-001 was formally accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) on July 30, 2026, under the expedited 30-working-day review pathway. The application sought authorization to initiate a first-in-human Phase 1 clinical trial of ACB’s lead MYC synthetic-lethal drug candidate.
The application followed the completion of JMBI-001’s IND-enabling development on June 1, 2026. This work included active pharmaceutical ingredient (API) manufacturing process development, oral formulation development, pharmacokinetic studies, and Good Laboratory Practice (GLP) toxicology studies. ACB directed the development program through its internal scientific and technical teams, in collaboration with specialized contract research and manufacturing organizations.
JMBI-001 is an investigational oral small-molecule drug candidate designed to exploit cellular vulnerabilities associated with deregulated MYC activity in cancer. Preclinical studies demonstrated antitumor activity across multiple tumor models, as well as antiangiogenic effects and treatment-induced antitumor immune responses.
The Phase 1 study is designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity in patients with advanced cancers. The findings will inform dose selection and subsequent clinical development.
About Anticancer Bioscience
Anticancer Bioscience (ACB) is a Chengdu-based biotechnology company developing innovative anticancer therapies that exploit cancer-specific dependencies. Its drug-development programs translate discoveries in cancer biology and synthetic lethality into novel therapeutic approaches.